Gene Review:
NAT1 - N-acetyltransferase 1 (arylamine N...
Homo sapiens
Synonyms:
AAC1, Arylamide acetylase 1, Arylamine N-acetyltransferase 1, MNAT, Monomorphic arylamine N-acetyltransferase, ...
Kukongviriyapan,
Phromsopha,
Tassaneeyakul,
Kukongviriyapan,
Sripa,
Hahnvajanawong,
Bhudhisawasdi,
Butcher,
Tetlow,
Cheung,
Broadhurst,
Minchin,
Rodrigues-Lima,
Dupret,
Arlt,
Glatt,
Muckel,
Pabel,
Sorg,
Schmeiser,
Phillips,
Moisio,
Sistonen,
Mecklin,
Järvinen,
Peltomäki,
Castelao,
Yuan,
Gago-Dominguez,
Skipper,
Tannenbaum,
Chan,
Watson,
Bell,
Coetzee,
Ross,
Yu,
Payton,
Johnson,
Bell,
Jonovska,
Budge,
Sim,
Al-Buheissi,
Cole,
Hewer,
Kumar,
Bryan,
Hudson,
Patel,
Nathan,
Miller,
Phillips,
Butcher,
Ilett,
Minchin,
Mitchell,
Warshawsky,
Lamberti,
Jungck,
Laarmann,
Knapp,
Caspari,
Friedl,
Sauerbruch,
Propping,
Kruse,
- Peroxynitrite irreversibly inactivates the human xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 (NAT1) in human breast cancer cells: a cellular and mechanistic study. Dairou, J., Atmane, N., Rodrigues-Lima, F., Dupret, J.M. J. Biol. Chem. (2004)
- Analysis of candidate modifier loci for the severity of colonic familial adenomatous polyposis, with evidence for the importance of the N-acetyl transferases. Crabtree, M.D., Fletcher, C., Churchman, M., Hodgson, S.V., Neale, K., Phillips, R.K., Tomlinson, I.P. Gut (2004)
- Metabolic activation of the environmental contaminant 3-nitrobenzanthrone by human acetyltransferases and sulfotransferase. Arlt, V.M., Glatt, H., Muckel, E., Pabel, U., Sorg, B.L., Schmeiser, H.H., Phillips, D.H. Carcinogenesis (2002)
- Variants of N-acetyltransferase NAT1 and a case-control study of colorectal adenomas. Lin, H.J., Probst-Hensch, N.M., Hughes, N.C., Sakamoto, G.T., Louie, A.D., Kau, I.H., Lin, B.K., Lee, D.B., Lin, J., Frankl, H.D., Lee, E.R., Hardy, S., Grant, D.M., Haile, R.W. Pharmacogenetics (1998)
- Association of GSTT1 non-null and NAT1 slow/rapid genotypes with von Hippel-Lindau tumour suppressor gene transversions in sporadic renal cell carcinoma. Gallou, C., Longuemaux, S., Deloménie, C., Méjean, A., Martin, N., Martinet, S., Palais, G., Bouvier, R., Droz, D., Krishnamoorthy, R., Junien, C., Béroud, C., Dupret, J.M. Pharmacogenetics (2001)
- NAT gene polymorphisms and susceptibility to Alzheimer's disease: identification of a novel NAT1 allelic variant. Johnson, N., Bell, P., Jonovska, V., Budge, M., Sim, E. BMC Med. Genet. (2004)
- Localization of N-acetyltransferases NAT1 and NAT2 in human tissues. Windmill, K.F., Gaedigk, A., Hall, P.M., Samaratunga, H., Grant, D.M., McManus, M.E. Toxicol. Sci. (2000)
- Arylamine N-acetyltransferase is required for synthesis of mycolic acids and complex lipids in Mycobacterium bovis BCG and represents a novel drug target. Bhakta, S., Besra, G.S., Upton, A.M., Parish, T., Sholto-Douglas-Vernon, C., Gibson, K.J., Knutton, S., Gordon, S., DaSilva, R.P., Anderton, M.C., Sim, E. J. Exp. Med. (2004)
- Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. Grant, D.M., Mörike, K., Eichelbaum, M., Meyer, U.A. J. Clin. Invest. (1990)
- Genetic polymorphisms in carcinogen metabolism and their association to hereditary nonpolyposis colon cancer. Moisio, A.L., Sistonen, P., Mecklin, J.P., Järvinen, H., Peltomäki, P. Gastroenterology (1998)
- The first 3D structure of arylamine N-acetyltransferase reveals a protease-like catalytic triad. Payton, M. Trends Pharmacol. Sci. (2000)
- Inhibitory effects of polyphenolic compounds on human arylamine N-acetyltransferase 1 and 2. Kukongviriyapan, V., Phromsopha, N., Tassaneeyakul, W., Kukongviriyapan, U., Sripa, B., Hahnvajanawong, V., Bhudhisawasdi, V. Xenobiotica (2006)
- Expression of arylamine N-acetyltransferases in pre-term placentas and in human pre-implantation embryos. Smelt, V.A., Upton, A., Adjaye, J., Payton, M.A., Boukouvala, S., Johnson, N., Mardon, H.J., Sim, E. Hum. Mol. Genet. (2000)
- Arylamine N-acetyltransferase type 2 and glutathione S-transferases M1 and T1 polymorphisms in familial adenomatous polyposis. Lamberti, C., Jungck, M., Laarmann, M., Knapp, M., Caspari, R., Friedl, W., Sauerbruch, T., Propping, P., Kruse, R. Pharmacogenetics (2002)
- Association of arylamine N-acetyltransferases NAT1 and NAT2 genotypes to laryngeal cancer risk. Henning, S., Cascorbi, I., Münchow, B., Jahnke, V., Roots, I. Pharmacogenetics (1999)
- Inactivation of human arylamine N-acetyltransferase 1 by the hydroxylamine of p-aminobenzoic acid. Butcher, N.J., Ilett, K.F., Minchin, R.F. Biochem. Pharmacol. (2000)
- Induction of human arylamine N-acetyltransferase type I by androgens in human prostate cancer cells. Butcher, N.J., Tetlow, N.L., Cheung, C., Broadhurst, G.M., Minchin, R.F. Cancer Res. (2007)
- N-Acetyltransferases, sulfotransferases and heterocyclic amine activation in the breast. Williams, J.A., Stone, E.M., Fakis, G., Johnson, N., Cordell, J.A., Meinl, W., Glatt, H., Sim, E., Phillips, D.H. Pharmacogenetics (2001)
- The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. McCarver, D.G., Hines, R.N. J. Pharmacol. Exp. Ther. (2002)
- The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: functional and localization studies. Windmill, K.F., McKinnon, R.A., Zhu, X., Gaedigk, A., Grant, D.M., McManus, M.E. Mutat. Res. (1997)
- Expression of cytochromes P450 and glutathione S-transferases in human prostate, and the potential for activation of heterocyclic amine carcinogens via acetyl-coA-, PAPS- and ATP-dependent pathways. Di Paolo, O.A., Teitel, C.H., Nowell, S., Coles, B.F., Kadlubar, F.F. Int. J. Cancer (2005)
- Regulation of the activity of the human drug metabolizing enzyme arylamine N-acetyltransferase 1: role of genetic and non genetic factors. Rodrigues-Lima, F., Dupret, J.M. Curr. Pharm. Des. (2004)
- Construction of Syrian hamster lines congenic at the polymorphic acetyltransferase locus (NAT2): acetylator genotype-dependent N- and O-acetylation of arylamine carcinogens. Hein, D.W., Doll, M.A., Rustan, T.D., Gray, K., Ferguson, R.J., Feng, Y. Toxicol. Appl. Pharmacol. (1994)
- Xenobiotic inducible regions of the human arylamine N-acetyltransferase 1 and 2 genes. Mitchell, K.R., Warshawsky, D. Toxicol. Lett. (2003)
- Stable expression of human CYP1A2 and N-acetyltransferases in Chinese hamster CHL cells: mutagenic activation of 2-amino-3-methylimidazo[4,5-f]quinoline and 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline. Yanagawa, Y., Sawada, M., Deguchi, T., Gonzalez, F.J., Kamataki, T. Cancer Res. (1994)
- Carotenoids/vitamin C and smoking-related bladder cancer. Castelao, J.E., Yuan, J.M., Gago-Dominguez, M., Skipper, P.L., Tannenbaum, S.R., Chan, K.K., Watson, M.A., Bell, D.A., Coetzee, G.A., Ross, R.K., Yu, M.C. Int. J. Cancer (2004)
- NAT2 slow acetylation and GSTM1 null genotypes may increase postmenopausal breast cancer risk in long-term smoking women. van der Hel, O.L., Peeters, P.H., Hein, D.W., Doll, M.A., Grobbee, D.E., Kromhout, D., Bueno de Mesquita, H.B. Pharmacogenetics (2003)
- Arylamine N-acetyltransferase type 2 (NAT2), chromosome 8 aneuploidy, and identification of a novel NAT1 cosmid clone: an investigation in bladder cancer by interphase FISH. Stacey, M., Matas, N., Drake, M., Payton, M., Fakis, G., Greenland, J., Sim, E. Genes Chromosomes Cancer (1999)
- The expression of xenobiotic-metabolizing enzymes in human prostate and in prostate epithelial cells (PECs) derived from primary cultures. Al-Buheissi, S.Z., Cole, K.J., Hewer, A., Kumar, V., Bryan, R.L., Hudson, D.L., Patel, H.R., Nathan, S., Miller, R.A., Phillips, D.H. Prostate (2006)
- Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Okkels, H., Sigsgaard, T., Wolf, H., Autrup, H. Cancer Epidemiol. Biomarkers Prev. (1997)